Skip to main content
NCBI home page
Springer logoLink to Springer
. 2018 Jun 23;97(9):1745. doi: 10.1007/s00277-018-3403-9

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Alexander Egle 1,2, Michael Steurer 3, Thomas Melchardt 1,2, Lukas Weiss 1,2, Franz Josef Gassner 2, Nadja Zaborsky 2, Roland Geisberger 2, Kemal Catakovic 2, Tanja Nicole Hartmann 2, Lisa Pleyer 1,2, Daniela Voskova 4, Josef Thaler 5, Alois Lang 6, Michael Girschikofsky 7, Andreas Petzer 8, Richard Greil 1,2,✉
PMCID: PMC6828337  PMID: 29934835

Correction to: Annals of Hematology

10.1007/s00277-018-3380-z

The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann.

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1007/s00277-018-3380-z

Articles from Annals of Hematology are provided here courtesy of Springer

RESOURCES